January 19, 2009
SAINT LAURENT, QUEBEC AND DUBLIN,
IRELAND--(MARKET WIRE)--Jan 19, 2009
-- IntelGenx Corporation (CDNX:
IGX.V
-
News)(OTC BB:
IGXT.OB
-
News) ("IntelGenx") and Circ
Pharma ("Circ") today announced a
partnership in which IntelGenx will
formulate, manufacture and supply to
Circ, and Circ will develop and
commercialise, a novel drug product
for the treatment of hyperlipidemia.
Under the terms of the agreement,
Circ Pharma will fund the
development of the product and
IntelGenx will receive royalties
from the product's sales. IntelGenx
will use its proprietary Versatab
technology to formulate the product.
This is the first product in a
series of Circ Pharma's controlled
release lipid lowering agents
specifically designed to target the
absorption of drug in order to
reduce the effective dose and
potentially lower the side effects.
The product is expected to reach the
market in 2012. The lipid lowering
market had over $30 billion in
worldwide sales during 2008.
"We are very pleased about this
collaboration with Circ Pharma. It
is another testament to our drug
development capabilities. We are
looking forward to a productive and
successful relationship with Circ
Pharma." said Dr. Horst Zerbe,
President and CEO of IntelGenx Corp.
About INTELGENX CORP.
IntelGenx Corp. is a drug
delivery company focused on the
development of oral
controlled-release products as well
as novel rapidly disintegrating
delivery systems. The Company uses
its unique multiple layer delivery
system to provide zero-order release
of active drugs in the
gastro-intestinal tract. IntelGenx
has also developed novel delivery
technologies for the rapid delivery
of pharmaceutically active
substances in the oral cavity based
on its experience with rapidly
disintegrating films. The Company's
research and development pipeline
includes products for the treatment
of pain, hypertension,
osteoarthritis, and depressive
disorders. More information is
available about the company at
www.intelgenx.com.
About CIRC PHARMA LIMITED
Circ Pharma is a specialty
pharmaceutical product development
company, based in Ireland, whose
mission is to develop differentiated
novel formulations of products based
on existing drugs that provide
incremental patient benefit. Circ
Pharma has a strong intellectual
property portfolio and technology in
the areas of targeted and
chronotherapeutic drug delivery with
pipeline of novel product
opportunities in a number of
indications including cardiovascular
and CNS/pain indications.
www.circpharma.com
FORWARD LOOKING STATEMENTS
This release may contain
forward-looking statements. Various
factors could cause actual results
to differ materially from those
projected in forward-looking
statements. Although the Company
believes that the forward-looking
statements contained herein are
reasonable, it can give no assurance
that the Company's expectations are
correct. All forward-looking
statements are expressly qualified
in their entirety by this cautionary
statement.
The TSX and OTCBB have neither
approved nor disapproved of the
information contained herein.
